Harbour BioMed
Mr. Weihao Xu, is the Chief Financial Officer and Chief Business Officer. Before HBM, Mr. Xu served as Chief Finance Officer at Alphamab Oncology, CASI Pharmaceuticals, and 111 Inc. Prior to that, he was active in the investment industry, working as the Portfolio Manager for Matthews Asia and several other international investment institutions, where he was responsible for global equity investments.
This person is not in any offices
Harbour BioMed
1 followers
Harbour BioMed is an Immune-Driven Global Bio-therapeutics Company discovering, developing and delivering Innovative Therapeutics for Oncology and Immunology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery - the H2L2 and the HCAb.